Journal of Diagnostics Concepts & Practice >

2025 , Vol. 24 >Issue 05: 542 - 547

DOI: https://doi.org/10.16150/j.1671-2870.2025.05.010

Review articles

Research advances in coagulation factor Ⅷ deficiency

  • XIE Liangzhe ,
  • DAI Jing ,
  • WU Wenman ,
  • WANG Xuefeng
Expand
  • Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2023-09-01

  Revised date: 2024-10-28

  Accepted date: 2024-12-05

  Online published: 2025-10-25

Fold

Abstract

Coagulation factor Ⅷ (FⅧ) deficiency is a rare bleeding disorder that can manifest as spontaneous or delayed life-threatening hemorrhage. FⅧ is composed of two catalytic subunits (FⅧ-A2) and two carrier (FⅧ-B2) subunits that have several functions in addition to its important role in hemostasis, including angiogenesis, maintenance of pregnancy, wound healing, and bone metabolism. FⅧ deficiencies can be classified as congenital or acquired according to etio-logy. The global incidence of congenital FⅧ deficiency is 0.05 per 100 000. Most patients with congenital FⅧ deficiency typically present with FⅧ-A deficiency. Acquired FⅧ deficiency, which typically arises from factors such as hyperconsumption and decreased synthesis, is more common than the congenital form. In rare instances, patients with acquired FⅧ deficiency may develop inhibitors targeting FⅧ subunits. The occurrence can be idiopathic or associated with comorbidities, such as malignancies or autoimmune disorders. A quantitative functional FⅧ activity assay is the first-line screening test for diagnosing FⅧ deficiency. For congenital FⅧ deficiency, enzyme-linked immunosorbent assays (ELISA) are required to determine the type of deficiency and to detect associated molecular genetic mutations. If acquired FⅧ deficiency is suspected, immunological tests are also required to detect inhibitors. Treatment primarily includes FⅧ replacement therapy and/or immunosuppressive therapy. Therapeutic options for FⅧ replacement have evolved from traditional fresh frozen plasma (FFP), old plasma, whole blood, and cryoprecipitate to plasma-derived and recombinant FⅧ concentrates. Although treatment targets and thresholds for FⅧ deficiency have not been clearly established, timely diagnosis and appropriate management of patients with severe FⅧ deficiency can significantly reduce the morbidity and mortality rates.

Key words： Coagulation factor Ⅷ deficiency; Acquired coagulation factor Ⅷ deficiency; Coagulation factor Ⅷ inhibitor; Coagulation disorder

Cite this article

XIE Liangzhe , DAI Jing , WU Wenman , WANG Xuefeng . Research advances in coagulation factor Ⅷ deficiency[J]. Journal of Diagnostics Concepts & Practice, 2025 , 24(05) : 542 -547 . DOI: 10.16150/j.1671-2870.2025.05.010

References

[1] YAN M T S, RYDZ N, GOODYEAR D, et al. Acquired factor Ⅷ deficiency: A review[J]. Transfus Apher Sci, 2018, 57(6):724-730.
[2] NADERI M, DORGALALEH A, TABIBIAN SH, et al. Current understanding in diagnosis and management of factor Ⅷ deficiency[J]. Iran J Ped Hematol Oncol, 2013, 3(4):164-172.
[3] MUSZBEK L, BERECZKY Z, BAGOLY Z, et al. Factor Ⅷ: a coagulation factor with multiple plasmatic and cellular functions[J]. Physiol Rev, 2011, 91(3):931-972.
[4] THOMAS V, EL ALAOUI S, MASSIGNON D, et al. Development and evaluation of a modified colorimetric solid-phase microassay for measuring the activity of cellular and plasma (factor Ⅷ) transglutaminases[J]. Biotechnol Appl Biochem, 2006, 43(Pt 3):171-179.
[5] KLEBER C, SABLOTZKI A, CASU S, et al. The impact of acquired coagulation factor Ⅷ deficiency in traumatic bleeding and wound healing[J]. Crit Care, 2022, 26(1):69.
[6] DORGALALEH A, NADERI M, HOSSEINI M S, et al. factor Ⅷ deficiency in Iran: a comprehensive review of the literature[J]. Semin Thromb Hemost, 2015, 41(3):323-329.
[7] DORGALALEH A, TABIBIAN S, HOSSEINI M S, et al. Diagnosis of factor Ⅷ deficiency[J]. Hematology, 2016, 21(7):430-439.
[8] LEVY J H, GREENBERG C. Biology of factor Ⅷ and clinical manifestations of factor Ⅷ deficiency[J]. Transfusion, 2013, 53(5):1120-1131.
[9] PELCOVITS A, SCHIFFMAN F, NIROULA R. Factor Ⅷ deficiency: A review of clinical presentation and management[J]. Hematol Oncol Clin North Am, 2021, 35(6):1171-1180.
[10] AMANO S, OKA K, SATO Y, et al. Measuring factor Ⅷ inhibitors in patients with factor Ⅷ deficiency: A case report and systematic review of current practices in Japan[J]. J Clin Med, 2022, 11(6):1699.
[11] PEYVANDI F, PALLA R, MENEGATTI M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders[J]. J Thromb Haemost, 2012, 10(4):615-621.
[12] KOSEKI-KUNO S, YAMAKAWA M, DICKNEITE G, et al. factor Ⅷ A subunit-deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages[J]. Blood, 2003, 102(13):4410-4412.
[13] ICHINOSE A, Japanese Collaborative Research Group on AH13. Autoimmune acquired factor Ⅷ deficiency due to anti-factor Ⅷ/13 antibodies: A summary of 93 patients[J]. Blood Rev, 2017, 31(1):37-45.
[14] ICHINOSE A, KOHLER H P, PHILIPPOU H. Recommendation for ISTH/SSC Criterion 2015 for autoimmune acquired factor Ⅷ/13 deficiency[J]. Thromb Haemost, 2016, 116(4):772-774.
[15] AHMAD F, SOLYMOSS S, POON M C, et al. Characte-rization of an acquired IgG inhibitor of coagulation factor Ⅷ in a patient with systemic lupus erythematosus[J]. Br J Haematol, 1996, 93(3):700-703.
[16] LIM W, MOFFAT K, HAYWARD C P. Prophylactic and perioperative replacement therapy for acquired factor Ⅷ deficiency[J]. J Thromb Haemost, 2004, 2(6):1017-1019.
[17] MUSZBEK L, PéNZES K, KATONA é. Auto- and alloantibodies against factor Ⅷ: laboratory diagnosis and clinical consequences[J]. J Thromb Haemost, 2018, 16(5):822-832.
[18] ICHINOSE A. Hemorrhagic acquired factor Ⅷ (13) deficiency and acquired hemorrhaphilia 13 revisited[J]. Semin Thromb Hemost, 2011, 37(4):382-388.
[19] AJZNER E, SCHLAMMADINGER A, KERéNYI A, et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor Ⅷ: a novel form of acquired factor Ⅷ deficiency[J]. Blood, 2009, 113(3):723-725.
[20] SOURI M, OSAKI T, ICHINOSE A. Anti-factor Ⅷ A subunit (FⅧ-A) autoantibodies block FⅧ-A2 B2 assembly and steal FⅧ-A from native FⅧ-A2 B2[J]. J Thromb Haemost, 2015, 13(5):802-814.
[21] LUO Y Y, ZHANG G S. Acquired factor Ⅷ inhibitor: clinical features, treatment, fibrin structure and epitope determination[J]. Haemophilia, 2011, 17(3):393-398.
[22] HAYASHI T, KADOHIRA Y, MORISHITA E, et al. A case of acquired FⅧ deficiency with severe bleeding symptoms[J]. Haemophilia, 2012, 18(4):618-620.
[23] NIJENHUIS A V, VAN BERGEIJK L, HUIJGENS P C, et al. Acquired factor Ⅷ deficiency due to an inhibitor: a case report and review of the literature[J]. Haematologica, 2004, 89(5):ECR14.
[24] KATONA é, MUSZBEK L. Diagnosis and management of congenital and acquired FⅧ deficiencies[J] Semin Thromb Hemost, 2016, 42(4):429-439.
[25] KOHLER H P, ICHINOSE A, SEITZ R, et al. Factor Ⅷ and fibrinogen SSC subcommittee of the ISTH. Diagnosis and classification of factor Ⅷ deficiencies[J]. J Thromb Haemost, 2011, 9(7):1404-1406.
[26] SCHROEDER V, KOHLER H P. Factor Ⅷ deficiency: an update[J]. Semin Thromb Hemost, 2013, 39(6):632-641.
[27] BOVET J, HURJáK B, DE MAISTRE E, et al. Autoimmune factor Ⅷ deficiency with unusual laboratory and clinical phenotype[J]. J Thromb Haemost, 2020, 18(6):1330-1334.
[28] DORGALALEH A, KAZEMI A, ZAKER F, et al. Laboratory diagnosis of factor Ⅷ deficiency, routine coagulation tests with quantitative and qualitative methods[J]. Clin Lab, 2016, 62(4):491-498.
[29] KARIMI M, PEYVANDI F, NADERI M, et al. Factor Ⅷ deficiency diagnosis: Challenges and tools[J]. Int J Lab Hematol, 2018, 40(1):3-11.
[30] BOEHLEN F, CASINI A, CHIZZOLINI C, et al. Acquired factor Ⅷ deficiency: a therapeutic challenge[J]. Thromb Haemost, 2013, 109(3):479-487.
[31] FRANCHINI M, FRATTINI F, CRESTANI S, et al. Acquired FⅧ inhibitors: a systematic review[J]. J Thromb Thrombolysis, 2013, 36(1):109-114.
[32] TONE K J, JAMES T E, FERGUSSON D A, et al. Acquired factor Ⅷ inhibitor in hospitalized and periope-rative patients: A systematic review of case reports and case series[J]. Transfus Med Rev, 2016, 30(3):123-131.
[33] MIESBACH W. Rituximab in the treatment of factor Ⅷ inhibitor possibly caused by Ciprofloxacin[J]. Thromb Haemost, 2005, 93(5):1001-1003.
[34] NGO SACK F, GALINAT H, EGRETEAU P Y, et al. Efficacy of rituximab in acquired factor Ⅷ inhibitor after arterial rFVIIa-induced thrombosis[J]. Haemophilia, 2013, 19(2):e93-e94.
[35] DREYFUS M, BARROIS D, BORG J Y, et al. Successful long-term replacement therapy with concentrate (Fibrogammin(?) P) for severe congenital factor Ⅷ deficiency: a prospective multicentre study[J]. J Thromb Haemost, 2011, 9(6):1264-1266.
[36] LASSILA R. Clinical use of factor Ⅷ concentrates[J]. Semin Thromb Hemost, 2016, 42(4):440-444.
[37] SEITZ R, DUCKERT F, LOPACIUK S, et al. ETRO Working Party on Factor Ⅷ questionnaire on congeniatal factor Ⅷ deficiency in Europe: status and perspectives. Study Group[J]. Semin Thromb Hemost, 1996, 22(5):415-418.
[38] MAHMOODI M, PEYVANDI F, AFRASIABI A, et al. Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran[J]. Blood Coagul Fibrinolysis, 2011, 22(5):396-401.
[39] JANBAIN M, NUGENT D J, POWELL J S, et al. Use of factor Ⅷ (FⅧ) concentrate in patients with congenital Ⅷ deficiency undergoing surgical procedures[J]. Transfusion, 2015, 55(1):45-50.
[40] DORGALALEH A, RASHIDPANAH J. Blood coagulation factor Ⅷ and factor Ⅷ deficiency[J]. Blood Rev, 2016, 30(6):461-475.
Options
Outlines

/

〈 〉